Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 10/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | AKR1C3 | P42330 | 3/20 | 0.42 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.42 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.42 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.39 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1079805 | 1.00 | PTGS2 (0.46) | PTGS2MAOBAKR1C3AKR1C2AKR1C1 | |
| SCHEMBL7806930 | 1.00 | PTGS2 (0.46) | PTGS2MAOBAKR1C3AKR1C2AKR1C1 | |
| SCHEMBL7813773 | 0.91 | PTGS2 (0.42) | PTGS2MAOBAKR1C3AKR1C2AKR1C1 | |
| SCHEMBL7813772 | 0.91 | PTGS2 (0.42) | PTGS2MAOBAKR1C3AKR1C2AKR1C1 | |
| SCHEMBL7802251 | 0.89 | PTGS2 (0.48) | PTGS2PTGS1ADORA3 | |
| SCHEMBL7802249 | 0.89 | PTGS2 (0.48) | PTGS2PTGS1ADORA3 | |
| SCHEMBL7887232 | 0.89 | PTGS2 (0.48) | PTGS2PTGS1ADORA3 | |
| SCHEMBL2126889 | 0.89 | AKR1C3 (0.46) | PTGS2AKR1C3AKR1C2AKR1C1PTGS1 | |
| SCHEMBL2126896 | 0.89 | AKR1C3 (0.46) | PTGS2AKR1C3AKR1C2AKR1C1PTGS1 | |
| SCHEMBL2126893 | 0.89 | AKR1C3 (0.46) | PTGS2AKR1C3AKR1C2AKR1C1PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 155 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200383983-A1 | CGRP ANTAGONISTS FOR THE TREATMENT OF MEDICATION OVERUSE HEADACHE, POST-TRAUMATIC HEADACHE, POST-CONCUSSION SYNDROME AND VERTIGO | ALLERGAN SALES, LLC | 2020-12-10 | — | — | US | claimed |
| US-20100111858-A1 | Diangostic and Therapeutic Cyclooxygenase-2 Binding Ligands | MALLINCKRODT LLC | 2010-05-06 | — | — | US | claimed |
| EP-2114461-A2 | DIAGNOSTIC AND THERAPEUTIC CYCLOOXYGENASE-2 BINDING LIGANDS | Mallinckrodt Inc. (US) | 2009-11-11 | — | — | EP | claimed |
| WO-2008091530-A2 | DIAGNOSTIC AND THERAPEUTIC CYCLOOXYGENASE-2 BINDING LIGANDS | MALLINCKRODT INC. (US) | 2008-07-31 | — | — | WO | claimed |
| EP-1608361-A4 | COMPOSITIONS OF CYCLOOXYGENASE-2 SELECTIVE INHIBITORS AND 5-HT1B/1D AGONISTS FOR THE TREATMENT AND PREVENTION OF MIGRAINE | PHARMACIA CORP (US) | 2006-08-16 | — | — | EP | claimed |
| US-20060160776-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and a cannabinoid agent for the treatment of central nervous system damage | PHARMACIA CORPORATION | 2006-07-20 | — | — | US | claimed |
| US-20060135506-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and a calcium modulating agent for the treatment of pain, inflammation or inflammation mediated disorders | PHARMACIA CORPORATION | 2006-06-22 | — | — | US | claimed |
| EP-1660079-A2 | COMPOSITIONS OF A CYCLOOXYGENASE-2 SELECTIVE INHIBITOR AND A SEROTONIN MODULATING AGENT FOR THE TREATMENT OF NEOPLASIA | Pharmacia Corporation (US) | 2006-05-31 | — | — | EP | claimed |
| US-20060105961-A1 | Method of using a cox-2 inhibitor and a topoisomerase II inhibitor as a combination therapy in the treatment of neoplasia | PHARMACIA CORPORATION (US) | 2006-05-18 | — | — | US | claimed |
| EP-1643995-A1 | TREATMENT OF MIGRAINE ACCOMPANIED BY NAUSEA | Pharmacia Corporation (US) | 2006-04-12 | — | — | EP | claimed |
| US-20040157848-A1 | Methods and compositions for the treatment of herpes virus infections using cyclooxygenase-2 selective inhibitors or cyclooxygenase-2 inhibitors in combination with antiviral agents | PHARMACIA CORPORATION | 2004-08-12 | — | — | US | claimed |
| WO-2004056349-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF HERPES VIRUS INFECTIONS USING CYCLOOXYGENASE-2 SELECTIVE INHIBITORS OR CYCLOOXYGENASE-2 INHIBITORS IN COMBINATION WITH ANTIVIRAL AGENTS | PHARMACIA CORPORATION (US) | 2004-07-08 | — | — | WO | claimed |
| EP-1207856-A2 | COFORMULATION METHODS AND THEIR PRODUCTS | Bradford Particle Design Limited (GB) | 2002-05-29 | — | — | EP | claimed |
| US-6302958-B1 | Sonic impinging jet crystallization apparatus and process | BRISTOL-MYERS SQUIBB COMPANY | 2001-10-16 | — | — | US | claimed |
| EP-0891345-B1 | NOVEL FURAN DIARYLMETHYLIDENE DERIVATIVES, METHOD FOR THEIR PREPARATION AND THERAPEUTICAL USES THEREOF | UNION PHARMA SCIENT APPL (FR) | 2001-08-16 | — | — | EP | claimed |
| WO-2001015664-A2 | COFORMULATION METHODS AND THEIR PRODUCTS | BRADFORD PARTICLE DESIGN LIMITED (GB) | 2001-03-08 | — | — | WO | claimed |
| WO-2000014082-A1 | DIARYLMETHYLIDENE FURAN DERIVATIVES AS DRUGS WITH ANTI-INFLAMMATORY, ANALGESIC AND CHEMOPREVENTIVE PROPERTIES | LABORATORIES UPSA (FR) | 2000-03-16 | — | — | WO | claimed |
| WO-1999021585-A1 | PHARMACEUTICAL COMBINATION OF A CYCLOOXIGENASE-2 INHIBITOR AND ACETAMINOPHEN OR AN OPIATE | LABORATOIRES UPSA (FR) | 1999-05-06 | — | — | WO | claimed |
| EP-0891345-A1 | NOVEL FURAN DIARYLMETHYLIDENE DERIVATIVES, METHOD FOR THEIR PREPARATION AND THERAPEUTICAL USES THEREOF | LABORATOIRES UPSA (FR) | 1999-01-20 | — | — | EP | claimed |
| WO-1997037984-A1 | NOVEL FURAN DIARYLMETHYLIDENE DERIVATIVES, METHOD FOR THEIR PREPARATION AND THERAPEUTICAL USES THEREOF | LABORATOIRES UPSA (FR) | 1997-10-16 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060105961-A1 | Method of using a cox-2 inhibitor and a topoisomerase II inhibitor as a combination therapy in the treatment of neoplasia | TOP2A, TOP2B, TOP1 | PTGS2 4/4885MAOB 1749/4885AKR1C3 1136/4885 |
| US-20100111858-A1 | Diangostic and Therapeutic Cyclooxygenase-2 Binding Ligands | PTGS2, PTGDR2, PTGES2 | PTGS2 1/4885MAOB 1213/4885AKR1C3 474/4885 |
| US-20040157848-A1 | Methods and compositions for the treatment of herpes virus infections using cyclooxygenase-2 selective inhibitors or cyclooxygenase-2 inhibitors in combination with antiviral agents | PTGS2, PTGES2, PTGS1 | PTGS2 1/4885MAOB 721/4885AKR1C3 390/4885 |
| US-20060135506-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and a calcium modulating agent for the treatment of pain, inflammation or inflammation mediated disorders | PTGS2, PTGES2, PTGS1 | PTGS2 1/4885MAOB 1721/4885AKR1C3 1657/4885 |
| US-20060160776-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and a cannabinoid agent for the treatment of central nervous system damage | CNR2, CNR1, PTGS2 | PTGS2 3/4885MAOB 577/4885AKR1C3 1491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.